Conatus Data First Step In Liver Drug Pivotal Trial Design
This article was originally published in Scrip
Conatus Pharmaceuticals Inc. reported mostly positive data from the first of two Phase II clinical trials that are meant to inform the design of pivotal trials for emricasan in the treatment of liver cirrhosis associated with alcoholism, non-alcoholic steatohepatitis (NASH) and the hepatitis C virus (HCV).
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.